Reversibility of Central Nervous System Adverse Events in Course of Art

Viruses

Giuseppe Vittorio De Socio¹  Antonio Di Biagio²  Filippo Del Puente²  Elena Ricci³  Lucia Taramasso⁴  Nicola Squillace⁵  Paolo Bonfanti⁵  Francesca Vichi⁶  Federico Conti⁷  Chiara Molteni⁸  Giustino Parruti⁹  Goffredo Angioni^1,10  Eleonora Sarchi^1,11  Antonio Cascio^1,12  Barbara Menzaghi^1,13  Carmela Grosso^1,14  Benedetto Maurizio Celesia^1,15  Giancarlo Orofino^1,16  Giordano Madeddu^1,17 

[1] Clinic of Infectious Diseases, Department of Medicine, Azienda Ospedaliera di Perugia, Santa Maria Hospital, 06129 Perugia, Italy;Department of Health Sciences, Infectious Disease Clinic, University of Genoa, 16145 Genoa, Italy;Fondazione ASIA Onlus, 20090 Buccinasco, Italy;Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, 16132 Genoa, Italy;Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, 20126 Monza, Italy;Infectious Diseases Unit 1, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, 50012 Florence, Italy;Infectious Diseases Unit, Department of Biomedical and Clinical Sciences “Luigi Sacco”, Università Degli Studi di Milano, 20122 Milan, Italy;Infectious Diseases Unit, Ospedale A. Manzoni, 23900 Lecco, Italy;Infectious Diseases Unit, Pescara General Hospital, 66020 Pescara, Italy;Infectious Diseases Unit, SS Trinità Hospital, 09121 Cagliari, Italy;Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, 15121 Alessandria, Italy;Infectious and Tropical Diseases Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90133 Palermo, Italy;Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, 21052 Busto Arsizio, Italy;Unit of Infectious Diseases, Cesena Hospital, 47521 Cesena, Italy;Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, 95123 Catania, Italy;Unit of Infectious Diseases, “Divisione A”, Amedeo di Savoia Hospital, 10149 Torino, Italy;Unit of Infectious and Tropical Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy;

关键词: CNS;    adverse events;    HIV;    dolutegravir;    reversibility;    neurocognitive;   

DOI  :  10.3390/v14051028

来源: DOAJ

【 摘 要 】

The purpose of this study is to evaluate the frequency of central nervous system adverse events (CNS-AE) on dolutegravir (DTG) and non-DTG containing ART, and their reversibility, in the observational prospective SCOLTA cohort. Factors associated with CNS-AE were estimated using a Cox proportional-hazards model. 4939 people living with HIV (PLWH) were enrolled in DTG (n = 1179) and non-DTG (n = 3760) cohorts. Sixty-six SNC-AE leading to ART discontinuation were reported, 39/1179 (3.3%) in DTG and 27/3760 (0.7%) in non-DTG cohort. PLWH naïve to ART, with higher CD4 + T count and with psychiatric disorders were more likely to develop a CNS-AE. The risk was lower in non-DTG than DTG-cohort (aHR 0.33, 95% CI 0.19–0.55, p < 0.0001). One-year follow-up was available for 63/66 PLWH with CNS-AE. AE resolution was reported in 35/39 and 23/24 cases in DTG and non-DTG cohorts, respectively. The probability of AE reversibility was not different based on ART class, sex, ethnicity, CDC stage, or baseline psychiatric disorder. At the same time, a lower rate of event resolution was found in PLWH older than 50 years (p = 0.017). In conclusion, CNS-AE leading to ART discontinuation was more frequent in DTG than non-DTG treated PLWH. Most CNS-AE resolved after ART switch, similarly in both DTG and non-DTG cohorts.

【 授权许可】

Unknown